Interferon-beta: Clinical Trials

6 trials of Interferon-beta, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 1 unknown. 6 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 3, Terminated 2, Unknown 1
Phase 23Terminated 2, Completed 1

Follow Interferon-beta: new trials by email Literature Review of Interferon-beta trials Research Report on Interferon-beta

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3), Interferon-beta - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Phase 1UnknownFundació Institut Germans Trias i Pujol162017-07-062023-07-07
Mesenchymal Stem Cells (MSC) for Ovarian Cancer
MSC-INFβ, Questionnaires - Ovarian Cancer
Phase 1CompletedM.D. Anderson Cancer Center52016-05-162019-07-18
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center82015-11-062022-03-22
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Aldesleukin, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Recurrent Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center42013-02-012017-04-19
Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
Interferon Beta - Acute Lung Injury, Acute Respiratory Distress Syndrome
Phase 1 / Phase 2CompletedFaron Pharmaceuticals Ltd372009-02-012015-05-27
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Interferon-beta - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 1CompletedBiogen122002-04-022020-11-17

Conditions studied

Carcinoma, Merkel Cell (2)  ·  Acute Lung Injury (1)  ·  Adenoviridae Infections (1)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Glioblastoma (1)  ·  Glioma (1)  ·  Gliosarcoma (1)  ·  Multiple Sclerosis (1)  ·  Multiple Sclerosis, Chronic Progressive (1)  ·  Multiple Sclerosis, Relapsing-Remitting (1)  ·  Ovarian Neoplasms (1)  ·  Respiratory Distress Syndrome (1)

Sponsors

Fred Hutchinson Cancer Center (2)  ·  Biogen (1)  ·  Faron Pharmaceuticals Ltd (1)  ·  Fundació Institut Germans Trias i Pujol (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (4)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Aude Chapuis (2)  ·  Alan Davidson, MD (1)  ·  Alexander Binning, MD (1)  ·  Amanda L. Olson, MD (1)  ·  Cristina Ramo, MD.PhD.Neurologist (1)  ·  Geoff Bellingan, MD (1)  ·  Martin Kuper, MD (1)  ·  Martin Stotz, MD (1)  ·  Mathew Wise, MD (1)  ·  Richard Beale, MD (1)  ·  Timothy Walsh, MD (1)

Results publications

PMID 24503265, PMID 31501122

NIH funding

P30CA015704 (2), 2015 (1), K24CA139052 (1), R01CA176841 (1)